Earlier quoted context omitted.
Yes, they can, but not in a blanket fashion where a test with a relatively high false positive rate and a relatively low sensitivity (between 18 and 50% for this particular test) is released without patient outcomes as the main driver of whether or not to apply the test absent further symptoms. Whether this test is one that can serve in that particular role is definitely not something that has already been determined…
Well, yes, it's only worth running a screening programme if you have a usefully accurate test and if you can then make some useful intervention after a positive result. Is anyone here disagreeing with that, though? Maybe we interpreted OP's comment that you quoted differently? I read it as being in favour of preventative medicine as a whole, not necessarily endorsing this specific test at this specific point in time.…
The people that have built this are at the forefront of this field, I've been following them for quite a while - since the announcement in March last year - it has direct bearing on some other things that I'm involved with and I'm hopeful that it will at first be a useful diagnostic tool and that in a later stage - after the kinks have been worked out and there is sufficient data - that it might help with more than that.
Preventative medicine obviously has its place and for selected cancers we are now in a phase where early detection leads to improved outcomes. But we should continue to be weary of overselling this - the same has already happened with other cancer tests.
Absent symptoms mass testing has serious risks and these will obviously be taken into account when setting policy, the article is actually reasonably neutral in this respect so I wonder why it leads to an immediate response that is equating this with a medical revolution. It may well be, but there is no evidence right now that this is the case.